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ABSTRACT 
 
Despite improved therapeutic regimens, primary CNS lymphoma (PCNSL) remains a 
therapeutic challenge. A prognostic classification of PCNSL patients may represent an 
important step towards optimized patient-adapted therapy. However, only higher age and low 
Karnofsky Performance Status (KPS) have repeatedly been reported to be associated with 
shorter overall survival (OS).  
Here we characterized microRNA (miRNA) fingerprints in the blood of PCNSL patients with 
short-term survival (STS) versus long-term survival (LTS) to assess their potential as novel 
prognostic biomarkers. Blood was collected from patients enrolled in the G-PCNSL-SG1 trial, 
a phase III study for patients with newly diagnosed PCNSL. miRNAs were extracted from the 
blood and analyzed by next generation sequencing.  
The STS group comprised 20 patients with a median OS of 3 months and was compared to 20 
LTS patients with a median OS of 55 months. The cohorts were balanced for age and KPS. 
Twelve annotated miRNAs were significantly deregulated between the two groups. Among 
them, miR-151a-5p and miR-151b exhibited the most prominent differences. Importantly, the 
combination of several miRNA allowed for a good separation between short- and long-term 
survivors with maximal AUC above 0.75. Besides the known miRNAs we identified putative 
novel miRNA candidates with potential regulatory influence of PCNSL. Finally, the 
differential regulation of the most promising candidate miRNAs was confirmed by real-time 
PCR in a validation cohort consisting of 20 STS and LTS patients.  
In conclusion, peripheral blood miRNA expression patterns hold promise as a prognostic tool 
in PCNSL patients. 
 
Key words: Primary CNS lymphoma, microRNA, biomarker, prognostic factor, next 
generation sequencing  
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INTRODUCTION 
 
Primary CNS lymphoma (PCNSL) is a malignant tumor, which is typically characterized by 
rapid growth causing severe clinical symptoms. In contrast to many other primary or 
secondary malignant brain tumors, PCNSL is a curable disease, at least in young patients who 
can tolerate aggressive therapeutic approaches. High-dose methotrexate (HD-MTX) is 
regarded the backbone of all current treatment strategies. The addition of various other drugs 
such as cytarabine, ifosfamide and high-dose chemotherapy with subsequent stem cell support 
has been assessed or is under clinical investigation (1, 2). Higher age and reduced 
performance status have repeatedly been described as prognostic factors associated with 
shorter survival (3-5). The definition of additional prognostic factors might be helpful to 
define patient populations that require an even more intense or prolonged therapy to delay 
tumor recurrence and unfavourable outcome. However, the search for other parameters 
supporting a prognostic discrimination has been widely futile except for some tissue markers 
including the expression of bcl-6 which has been associated with a favourable course of the 
disease (6). Furthermore, it has been reported that intraocular involvement in PCNSL may 
represent a negative prognostic indicator (7). In contrast, the relevance and application of 
minimally invasive biomarkers such as blood-borne patterns (e.g. LDH) has been discussed 
controversially (4). 
microRNAs (miRNA) are short non-coding RNA molecules which act as post-transcriptional 
regulators of gene expression (8) and are frequently deregulated under pathological conditions 
(9). Little is known about the expression and function of miRNAs in the context of PCNSL. 
In PCNSL tumor tissue, the miRNA expression repertoire is different to that found in 
systemic non-Hodgkin lymphomas (10). miRNAs have also gained increasing interest as 
biomarkers isolated from tumor tissue, blood or cerebrospinal fluid (CSF) for diagnostic and 
prognostic purposes (11). A deregulated expression of single miRNAs in the CSF of PCNSL 
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patients compared to healthy controls has been observed (12). In contrast, blood-derived 
miRNA profiles have not yet been assessed in PCNSL patients. Owing to the fact that blood is 
easily and repeatedly accessible, blood-borne miRNAs are of particular interest as 
biomarkers. 
G-PCNSL-SG1 is the only completed phase III study in PCNSL (13). Using blood samples 
collected from immunocompetent patients with newly diagnosed PCNSL who entered the 
trial, we aimed at defining differences in the blood-derived miRNA expression patterns of two 
cohorts of patients with short- and long-term survival (STS, LTS). All miRNA samples were 
analyzed using massively parallel, next generation sequencing (NGS) and subsequently 
validated using quantitative real-time polymerase chain reaction (PCR). We hypothesized that 
differences in peripheral blood miRNA profiles may represent suitable biomarkers which can 
be exploited for prognostic purposes and eventually clinical decision making. 
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MATERIALS AND METHODS 
 
Samples 
Blood samples were obtained from patients with confirmed diagnosis of PCNSL at the time of 
enrolment in the G-PCNSL-SG1 study. Within this trial, all patients initially received HD-
MTX-based chemotherapy followed by whole brain radiotherapy (WBRT), salvage 
chemotherapy or observation as defined in the protocol. No maintenance therapy with 
rituximab or any chemotherapeutic agent was administered (13). Written informed consent 
was obtained from all patients before blood sampling. Blood was collected using EDTA tubes 
which were subsequently frozen at -80 °C until further processing. In total, 20 patients who 
succumbed to tumor early in the disease course were chosen for the STS group. Another 20 
patients with favourable course were grouped for the cohort of long-term survivors (LTS). A 
prior power analysis has demonstrated that these cohort sizes at an alpha error probability of 
0.05 and a statistical power of 0.95 require an effect size of below 1.2. In previous studies, we 
usually discovered miRNAs with respective power and these miRNAs were frequently 
successfully validated by real-time PCR (14, 15).  
 
miRNA extraction and NGS 
For the extraction of miRNA, the cellular fractions were pelleted by centrifugation and further 
processed using the miRNeasy kit (Qiagen GmbH, Hombrechtikon, Switzerland) (16). RNA 
samples were subjected to analysis by NGS. In brief, 1 µg of total RNA per sample was used 
for library preparation. For quantification, the RNA 6000 Pico Chip on the Bioanalyzer 2100 
(Agilent, Santa Clara, CA) was employed. Subsequently, the NEBNext Small Library Prep 
Kit (New England BioLabs, Beverly, USA) was applied according to the manufacturer’s 
instruction. The resulting libraries were measured with the Bioanalyzer using the DNA 1000 
Chip and subsequently pooled in batches of ten samples in equal amounts. Sequencing 
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libraries were then clustered with a final concentration of 10 pmol with 1% PhiX control in 
one lane each of a 50 bp single read flowcell using the cBot (Illumina). Sequencing of 50 
cycles was performed on a HiSeq 2000 (Illumina). De-multiplexing of raw sequencing data 
and generation of fastq files was done using bcl2fastq 1.8.3. 
 
Statistical analysis 
As a first step, the pre-processing of the Illumina HiSeq raw reads was carried out. In the 
beginning, the 3' adapter sequences were cut using the program fastx_clipper from the 
FASTX-Toolkit. Subsequently, we applied the miRDeep2 pipeline for retrieving the miRBase 
counts for release v20 and prediction of novel miRNAs. All further downstream statistical 
analyses were carried out using the freely available statistical programming language R 
(version 3.0.2; http://cran.r-project.org/). Data were normalized by quantile normalization in 
order to account for systematic shifts in read counts per sample. The resulting data matrix was 
used as input for all further downstream analyses carried out in R. Prior to employing t-test, 
the approximate normal distribution of the measured miRNAs was tested by Shapiro-Wilk 
test followed by adjustment for multiple testing. Next, miRNAs showing a different behaviour 
between long- and short-time survivors were identified by unpaired two-tailed parametric t-
test. Significance values (p-values) obtained for each individual miRNA were adjusted for 
multiple testing by Benjamini-Hochberg adjustment (17). For novel miRNAs, we additionally 
calculated significance values using the non-parametric Wilcoxon-Mann-Whitney test, which 
does not rely on the assumption that data have to be normally distributed. As additional 
measure, a Receiver Operating Characteristic (ROC) analysis was carried out and the Area 
Under Curve (AUC) value of miRNAs was computed separately. AUC values are in the range 
from 0 to 1, where a value of 0.5 indicates random distribution of variations among STS and 
LTS, corresponding to the least diagnostic information content of a biomarker. An AUC value 
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of 1 means that all expression intensities of the respective miRNA are higher in LTS (up-
regulated miRNA). Accordingly, an AUC of 0 means that all expression values of the miRNA 
are higher in STS (down-regulated biomarker).  
In addition to this single biomarker analysis, which does not account for potentially improved 
diagnostic information content by combining the predictive power of different markers, 
samples were subjected to a classification analysis using Support Vector Machines (SVM) 
implemented in the R e1071 package (15). For classification, we determined the specificity, 
sensitivity and accuracy. The specificity corresponds to the percentage of correctly identified 
controls, i.e., true negatives divided by true negative plus false positives. A true negative (TN) 
denotes a LTS that is actually recognized, while a false positive (FP) represents a LTS 
predicted to be a STS. Similarly, the sensitivity corresponds to the percentage of correctly 
identified STS, i.e., true positives divided by true positives plus false negatives. Here, a true 
positive (TP) denotes a short-term survivor that is actually recognized, while a false negative 
(FN) represents a short-term survivor that is wrongly recognized. The accuracy represents the 
percentage of correct predictions, i.e. (TN + TP)/(TN + TP + FN + FP). Following 
classification, non-parametric permutation tests were carried out in order to check for 
potential overtraining. Here, the class labels were sampled at random and classifications were 
carried out using the permuted class labels. All statistical analyses were performed using the 
R program as previously described (18).  
For miRNA enrichment analysis, the tool for annotations of microRNAs (TAM) was applied 
(19). Specifically, all miRNAs that were influenced by short- or long-term survival were 
compared to the background set of all miRNAs included in the NGS study. Enrichment was 
carried out for the precursor molecules and all categories with a p-value < 0.05 were 
considered significant if at least 2 miRNAs were located in the respective category. If not 
indicated otherwise, significance values correspond to raw p-values 
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Real-time reverse transcription (RT)-PCR 
An ABI PRISM 7000 Sequence Detection System and TaqMan microRNA assays (Applied 
Biosystems, Rotkreuz, Switzerland) were used for quantification of miRNA expression by 
real-time PCR. RNU48 which was established before as an appropriate endogenous control 
for blood cell-derived miRNAs was used for normalization (16, 20). The following conditions 
were applied for all PCR reactions: 40 cycles of 95°C for 15 s and 60°C for 60 s. Data 
analysis was done using the ∆∆CT method for relative quantification as previously specified 
(21).  
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RESULTS 
 
Prognostic factors that may be helpful to classify patients and adapt treatment decisions are 
rare in PCNSL. We aimed at defining the potential use of peripheral blood miRNAs as 
prognostic markers. To this end, we set up two groups of patients who differed significantly in 
their survival times. The group of patients who died early (STS) had a median OS of 3 
months. In contrast, the LTS group had a median OS of 55 months. Importantly, both cohorts 
were balanced for the well-known prognostic factors age and KPS (5). The median age in the 
STS group was 64 years, ranging from 53 to 80 years. In the LTS group, median age was 62 
(range 42-81). Median KPS at the time of study enrolment was 70% for both groups. Within 
the group of short-term survivors, 11/20 patients received only HD-MTX but no further 
treatment because of rapid tumor progression and subsequent death. From the 20 long-term 
survivors, 3 received HD-MTX alone, 6 had HD-MTX-based chemotherapy followed by 
WBRT according to the study protocol and 11 patients were initially treated with HD-MTX 
and received salvage therapy at tumor recurrence. A detailed overview of patients’ 
characteristics is provided in Suppl. Table 1. In order to report PCNSL biomarker profiles, we 
first carried out a single marker analysis, followed by machine learning technologies to cluster 
miRNA profiles. Finally, we confirmed the biomarker candidates by real-time RT-PCR in a 
validation cohort. 
 
Single marker analysis 
All blood samples from the STS and LTS group were analyzed by NGS. All known miRNAs 
that are listed in the Sanger miRBase version 20 were analyzed using computational 
approaches. First, the lowly abundant or not expressed miRNAs (median of 10 raw reads) 
were excluded from the analysis such that 499 miRNAs remained. A comparison of the 
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miRNA expression between the two groups displayed a significant deregulation of 12 
miRNAs, reflecting 2.4% of all 499 expressed miRNAs. In the LTS group, 9 miRNAs were 
up-regulated while 3 miRNAs were down-regulated. After adjustment for multiple testing, 
however, none of the miRNAs remained significant. This is likely due to the restricted sample 
number relative to the very high number of miRNAs. Nevertheless, the raw p-values showed 
a tendency to accumulate at lower p-values (Fig. 1), potentially indicating significant markers 
that may be validated by real-time RT-PCR. All significantly deregulated miRNAs identified 
by NGS are shown together with the respective error bars in Figure 2. As further criterion for 
the diagnostic performance of the biomarker candidates we evaluated the area under the curve 
(AUC) in a receiver operator characteristics (ROC) analysis. Especially the three down-
regulated biomarker candidates showed a high standard deviation leading to limited AUC 
values, restricting their use as single biomarkers. Within the group of up-regulated miRNAs 
we found four with particularly high AUC values (> 0.7): miR-151a-5p, miR-151b, miR-
106a-5p and miR-17-5p. The respective ROC curves are presented in Figure 3A. We also 
asked whether miRNA expression correlates with therapy response. To this end, we grouped 
the patients based on their best response to MTX-based therapy in those with complete 
remission (n = 14) and progressive disease (n = 16). For this comparison the same 
calculations as presented above were carried out. Here, we discovered 37 miRNAs with a 
high AUC value above 0.75, containing many candidates from the previous analysis including 
miR-151a-5p, miR-151b, miR-183-3p and miR-96-5p, which are exemplarily shown in Figure 
3B. These results indicate that the expression of several miRNAs correlates with response to 
therapy. 
In order to further support our hypothesis that miRNAs are reasonable biomarkers for 
predicting the survival time of PCNSL patients, we carried out a survival time analysis. To 
this end, each miRNA was split in a highly expressed and lowly expressed group, where 
highly expressed means that the respective miRNA for a patient was above the average value. 
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For each marker, a survival time analysis was carried out separately. Using the binary 
variable, we calculated survival curves, which revealed a statistically significant miRNA-
dependent survival for 15 of the expressed miRNAs (Fig. 4). Since this analysis addresses a 
similar question as the above described t-tests, the results show a certain overlap such as miR-
183-3p that was detected in both approaches.  
Further analysis of the NGS dataset demonstrated the presence of short RNA molecules with 
putative miRNA function that had not been described before. We sorted RNA 
oligonucleotides, which had to be considered as fragments of mRNAs as outlined in the 
methods part. The remaining RNA molecules may represent novel miRNA and are identified 
for the first time within our analysis. The respective marker candidates that deserve further 
validation were denoted as PCNSL-miR-XXX, where the miRNAs were numbered in 
increasing order. Many of the putative novel miRNAs were excluded in a filtering step since 
they mapped to other RNAs. Next, according to the known miRNAs, low abundant miRNA 
candidates were filtered out such that 49 miRNAs remained. Of the 49 markers, three 
miRNAs were deregulated between STS and LTS patients including PCNSL-miR-28, 
PCNSL-miR-901 and PCNSL-miR-904 as determined by t-test, one additional marker, 
PCNSL-miR-31, was significant according to a non-parametric Wilcoxon-Mann-Whitney test 
(see Materials and Methods section). Detailed information for these four miRNAs is provided 
in Suppl. Table 2. 
 
Complex miRNA signatures 
Single deregulated miRNAs from the blood will hardly be useful as prognostic biomarkers. 
However, the respective markers can be combined in order to reach improved statistical 
power. To approach complex profiles we first asked whether the miRNAs with diagnostic 
information content as discovered above may be linked to specific pathological conditions 
and thereby provide valuable information concerning the underlying pathobiology. Within the 
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group of abundantly expressed miRNAs, we observed several molecules that are known to be 
involved in various physiological and pathological processes. We thus carried out a down-
stream miRNA enrichment analysis using the tool for annotations of microRNAs (TAM) that 
includes different miRNA families, data from the human miRNA and disease database 
(HMDD) (19) and information on various functional classifications of miRNAs. As input for 
TAM, we used all miRNAs with significance values below 0.1 to increase the sensitivity of 
our downstream analysis. Altogether, TMA revealed several significantly enriched categories 
including the subgroup “onco-miRNAs” with highest significance (p = 0.0007), followed by 
“immune system” and “B cell lymphoma” (p-value of 0.005), as detailed in Suppl. Table 3.  
The examination of numerous miRNAs allows for the generation of complex miRNA 
fingerprints in the blood that serve as basis for the classification of the samples as STS or 
LTS. Using statistical learning techniques, we carried out 25 iterations of a 10-fold cross-
validation and likewise 25 non-parametric permutations with random class labels, i.e. each 
sample has been assigned to either the short or the long time survivor class. To determine a 
suitable subset of miRNA biomarkers, we started the training process with the two most 
significantly deregulated markers and in a stepwise forward approach iteratively increased the 
number of miRNAs contributing to the classification (in order of increasing p-values 
according to t-test). This filtering-based feature selection approach, which does not consider 
correlations between miRNAs, was repeated until all miRNAs were included. Combining 
multiple miRNAs resulted in an improved classification performance. The respective box 
plots showing the highly significant results are presented in Figure 5. Here, the three red 
boxes represent the result of the classification accuracy, specificity and sensitivity. In contrast, 
the blue boxes can be considered as background value for the classification. Using this 
procedure, the maximal AUC of the repeated cross-validations was 0.755, being above the 
values of the most significant single markers as presented above. Although this classification 
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performance is not yet ready to allow for clinical application, increased data sets bear the 
potential to improve the subset selection and classification process substantially. 
 
Real-time PCR validation 
Finally, we aimed at validating the differential expression of known miRNAs as well as 
putative novel miRNAs between short- and long-term survivors in a second, independent 
cohort of patients. Again, we set up two groups of patients from the G-PCNSL-SG1 trial 
differing in the survival time. Median OS in the validation group was 6 months for STS and 
35 months for LTS, respectively. We chose 10 deregulated miRNAs identified by NGS for 
confirmation in the validation cohort including three newly identified putative miRNAs. 
Using real-time PCR, we observed a consistent deregulation of 8 out of 10 tested miRNAs in 
the same direction as demonstrated by NGS indicating that similar results can be obtained in a 
second cohort of patients (Fig. 6). 
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DISCUSSION 
 
Biomarkers that allow for a prognostic classification of patients can be an important tool for 
optimal patient-adapted therapy and are urgently needed in PCNSL. However, well 
established prognostic markers in PCNSL are rare. Besides age and performance status, the 
prognostic score of the International Extranodal Lymphoma Study Group (IELSG) includes 
elevated serum lactate dehydrogenase (LDH) levels, high CSF protein concentrations, and the 
involvement of deep regions of the brain (4). However, the most recent prognostic score for 
PCNSL patients finally only confirmed age and performance status as prognostic factors upon 
multivariate analysis (5). Consequently, biomarkers from the blood have not been established 
for PCNSL. Conflicting results were reported for the prognostic suitability of serum LDH 
levels (4, 22), most likely because LDH levels can be influenced by various pathological 
conditions. In contrast, complex miRNA profiles obtained from the blood are typically 
disease-specific and can even differ between different pathological conditions from the same 
organ such as the brain (16, 23). Based on these considerations, we examined two groups of 
patients, which differed in their survival times for our miRNA assessment. Because of the 
limited number of available blood samples from patients entering the G-PCNSL-SG1 trial, the 
size of the STS and LTS groups used for the discovery step was restricted to 20 patients each. 
The STS and LTS groups were balanced for sex and the only repeatedly approved prognostic 
factors age and performance status (Suppl. Table 1). However, we cannot fully exclude that 
other variables beyond these parameters may have been different between the two groups. 
Therefore, the results of our study need to be confirmed in larger patient cohorts, which may 
help to reduce the risk of other confounding factors. 
All analyses were done using NGS, which, in contrast to microarrays or PCR, also allowed 
detecting novel putative miRNAs, which had not been known before (Suppl. Table 2). 
Furthermore, NGS enabled the characterization of comprehensive miRNA expression patterns 
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consisting of several miRNA, which typically yields higher diagnostic information than a 
single marker. The NGS approach used for our study revealed several miRNA that are 
differentially expressed in the blood of STS and LTS patients (Fig. 2). As expected, the 
differentiation between STS and LTS patients based on single miRNAs (Fig. 3) could be 
improved when complex miRNA expression patterns were analyzed (Fig. 5) highlighting the 
advantages of comprehensive miRNA patterns compared to other potential biomarkers which 
are typically only univariate markers. Survival analyses confirmed the potential of miRNAs as 
a prognostic tool. In this analysis, where miRNAs were split in low and high abundant, we 
demonstrated a clear correlation with overall survival as shown for 15 survival curves with a 
p-value below 0.01 (Fig. 4). Since the STS and LTS groups had substantially different 
survival times according to patient selection, these findings need to be confirmed in a larger 
cohort.  
Because of the limited number of available blood samples, only a small proportion of patients 
treated within the G-PCNSL-SG1 trial could be assessed. The rather small size of the training 
and confirmation group represents a limitation of our analysis. However, 8 out of 10 
deregulated miRNA identified by NGS in the training group were confirmed to be 
differentially regulated in the second set of short- and long-term survivors (Fig. 6). Two 
miRNAs were non concordant between both technologies and cohorts (upper left quadrant of 
the figure). Potential reasons for the divergence between real-time PCR and NGS besides the 
biological diversity include the nucleic acid composition and the secondary structure of 
miRNAs.  
The results of our study stress the suitability of miRNAs as biomarkers in PCNSL. In addition 
to a previous study, which demonstrated that miRNAs in the CSF can discriminate between 
samples of PCNSL patients and healthy controls (12), our study reveals that miRNAs may be 
valuable tools for the prognostic classification of PCNSL patients. Three single miRNAs in 
the CSF have been assessed for their use as monitoring parameters during the course of the 
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disease (24). Compared to CSF-derived molecules, blood-based biomarkers are easier 
accessible and can be obtained in parallel to routine blood sampling. Whether miRNAs in the 
blood can be used for the monitoring of PCNSL patients needs to be defined within a larger 
cohort of patients in a prospective manner. The analysis of miRNA expression patterns can be 
performed rapidly using NGS, microarrays or PCR. The confirmation of our NGS results by 
real-time PCR indicates that miRNA-based analyses are feasible with technologies that are 
broadly available in the clinical routing setting. Overall, the findings of our proof-of-concept 
study suggest that miRNA expression signatures in the blood are associated with the 
prognosis of PCNSL patients. Accordingly, such miRNA fingerprints in the blood may allow 
for a prognostic stratification of PCNSL patients and ultimately help to improve the 
therapeutic management. 
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Figure legends 
 
Fig. 1. Distribution of raw p-values for the deregulation of individual miRNAs. 499 
miRNAs were abundant enough to allow for reliable bioinformatics evaluation. Expression 
levels in the STS (n=20) and LTS (n=20) cohorts were compared by unpaired two-tailed 
parametric t-test and the number of individual p-values falling into the respective segments of 
width 0.05 was plotted as histogram. The vertical black line denotes the alpha level of 0.05.  
 
Fig. 2. Median expression of the 12 significantly deregulated markers. Expression levels 
as determined by NGS are indicated. 
 
Fig. 3. ROC curves for deregulated miRNA candidates. The blue shaded field indicates the 
95% confidence interval for the ROC curve. A. Comparison of STS and LTS patients. B. 
Analysis of samples from patients achieving a complete remission (CR) compared to patients 
experiencing progressive disease (PD).  
 
Fig. 4. miRNAs predict survival of PCNSL patients. For each miRNA, a survival time 
analysis was carried out using the average expression value as cut-off for separation between 
low and high expression. Survival curves are shown for 15 miRNAs, which allowed a 
statistically significant separation between short- and long-term survivors. Red color indicates 
that a miRNAs is highly expressed, while green corresponds to miRNAs with low expression 
as detailed in the methods section. 
 
Fig. 5. Classification of samples from short- and long-term survivors. Accuracy, 
specificity and sensitivity were evaluated using repeated runs of 10-fold cross-validation. Red 
21 
 
boxes correspond to actual classification results while blue boxes correspond to permutation 
tests used as control.  
 
Fig. 6. Differentially regulated miRNAs identified by NGS can be confirmed in a second 
cohort of patients. The expression of selected miRNAs that were found to be deregulated by 
NGS was assessed by qPCR in a second cohort of STS and LTS PCNSL patients. Arrows 
indicate the shift of regulation in the two cohorts as determined by the two techniques. Novel 
miRNAs identified with the NGS approach are named with “PCNSL-miR-xxx”. 
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